parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (6650 nCPM)	1.00
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	12 Parkinson's papers of 155	0.66
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 8196

PPP2R2B in oligodendrocytes, braak+0.20 (p 0.597) → +0.12 (p 0.756)receipt 8202
PPP2R2B in dopamine neurons, braak+0.16 (p 0.685) → +0.16 (p 0.685)receipt 8203

receipt 8203: PPP2R2B in dopamine neurons, braak

power: full sample +0.17 (p 0.498, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.21 (p 0.393, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.15 (p 0.544, n 18). could be the mix.
skeptic: leave-one-out range +0.06 to +0.33, sign flips 0; without severely affected donors +0.17 (p 0.498, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PPP2R2B in dopamine neurons.

case closed: nothing better to follow up.

receipt 8202: PPP2R2B in oligodendrocytes, braak

power: full sample +0.17 (p 0.509, n 18), 95% CI -0.33 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.18 (p 0.471, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.17 (p 0.493, n 18). could be the mix.
skeptic: leave-one-out range +0.06 to +0.29, sign flips 0; without severely affected donors +0.17 (p 0.509, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PPP2R2B in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts